Compare CVS Health Corp (CVS) vs Dow Inc (DOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Dow Inc — how do they compare? CVS Health Corp trades at $86.82 (market cap $112.49B), while Dow Inc trades at $28.35 (market cap $20.06B). The key difference: CVS Health Corp is far larger — about 5.6× Dow Inc's market cap, and Dow Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Dow Inc for 82 Days on average.
| CVS | DOW | |
|---|---|---|
Market Cap | $112.49B | $20.06B |
Volume | 8,467,392 | 7,817,231 |
Sector | Health | Basic Materials |
52-Week High | $110.60 | $41.87 |
52-Week Low | $70.08 | $20.65 |
Typical Hold Time | 83 Days | 82 Days |
Enterprise Value | $174.83B | $35.75B |
Dividend Yield | 3.02% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
DOW trades at $27.77, down 1.38% with bearish technical signals. The company shows mixed fundamentals with negative net income margin of -3.13% and ROE of -7.86%, though recent earnings have beaten expectations. Cash flow trends show operational improvement from $1.03B in 2025 to projected $3.9B in 2026. Analyst consensus is mixed with 27.8% buy ratings and a $34.22 price target, representing 23% upside potential.
While DOW faces margin pressures and declining revenue, the stock trades at attractive valuation multiples with P/S of 0.48. The dividend remains intact with $0.35 payment scheduled for September 2026. Key risks include ongoing profitability challenges and chemical sector headwinds, but earnings beats and cash flow improvement provide potential catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →
